

I hereby certify that this paper (along with any paper referred to as being attached or enclosed) is being transmitted via the Office electronic filing system in accordance with § 1.6(b)(4).

Dated: 4/9/09

Signature: 

(Dorena Macedo)

Docket No.: 249.P2
(PATENT)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of:
Mark W. Becker et al.

Application No.: 10/785,497

Confirmation No.: 9922

Filed: February 24, 2004

Art Unit: 1657

For: PRODRUGS OF PHOSPHONATE
NUCLEOTIDE ANALOGUES AND
METHODS FOR SELECTING AND
MAKING SAME

Examiner: P. C. Martin

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT (IDS)
AND CO-PENDING APPLICATION INFORMATION

MS Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Madam:

Pursuant to 37 CFR 1.56, 1.97 and 1.98, the attention of the Patent and Trademark Office is hereby directed to the references listed on the attached PTO/SB/08. It is respectfully requested that the information be expressly considered during the prosecution of this application, and that the references be made of record therein and appear among the "References Cited" on any patent to issue therefrom.

This Information Disclosure Statement is filed more than three months after the U.S. filing date, OR more than three months after the date of entry of the national stage of a PCT application, AND after the mailing date of the first Office Action on the merits,

whichever occurs first, but before the mailing date of a Final Office Action or Notice of Allowance (37 CFR 1.97(c)).

In accordance with 37 CFR 1.98(a)(2)(ii), Applicant has not submitted copies of U.S. patents and U.S. patent applications. Applicant submits herewith copies of foreign patents and non-patent literature in accordance with 37 CFR 1.98(a)(2).

In accordance with 37 CFR 1.97(g), the filing of this Information Disclosure Statement shall not be construed to mean that a search has been made or that no other material information as defined in 37 CFR 1.56(a) exists. In accordance with 37 CFR 1.97(h), the filing of this Information Disclosure Statement shall not be construed to be an admission that any patent, publication or other information referred to therein is "prior art" for this invention unless specifically designated as such.

The Examiner is advised that the following co-pending application contains subject matter that may be related to the present application. By bringing this application to the Examiner's attention, Applicant does not waive the confidentiality provisions of 35 U.S.C. § 122.


Application Number	Filing Date	Art Unit
12/110,829	04/28/2008	1657

It is submitted that the Information Disclosure Statement is in compliance with 37 CFR 1.98 and the Examiner is respectfully requested to consider the listed references.

Please charge our Deposit Account No. 07-1250 in the amount of \$180.00 covering the fee set forth in 37 CFR 1.17(p). The Director is hereby authorized to charge any deficiency in the fees filed, asserted to be filed or which should have been filed herewith (or with any paper hereafter filed in this application by this firm) to our Deposit Account No. 07-1250, under Order No. 249.P2.

Dated: 6/8/09

Respectfully submitted,

By 
Allan N. Kutzenco
Registration No.: 38,945
GILEAD SCIENCES, INC.
333 Lakeside Drive
Foster City, California 94404
(650) 522-6101
(650) 522-5575 (Fax)
Attorney For Applicant